Almitrine: a possible therapeutic strategy for COVID-19?

Renata Maria De Carvalho Cremaschi,Fernando Morgadinho Santos Coelho,Cristina Frange,Lia Rita De Azeredo Bittencourt

doi:10.34024/rnc.2020.v28.10941

Renata Maria De Carvalho Cremaschi, Fernando Morgadinho Santos Coelho + Show 2 more

Open Access

https://doi.org/10.34024/rnc.2020.v28.10941

Copy DOI

Journal: Revista Neurociências	Publication Date: Oct 23, 2020
License type: CC BY 4.0

Abstract

Coronavirus disease 2019 (COVID‐19) remains with no specific treatment, despite the efforts of many scientists around the world. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) penetrates human host banknotes through interaction with angiotensin-converting enzyme 2 and transmembrane protease, serine 2 (TMPRSS2) receptors, located at respiratory tract (upper and lower) and the olfactory epithelium (pathway to the Central Nervous System). The virus causes COVID-19 and sometimes a Severe Acute Respiratory Syndrome (SARS). Several neurological manifestations can be associated with the infection. The SARS-COV-2 neurotropism for cardiorespiratory centers, causing autonomic damage, may contribute to respiratory failure. Almitrine is a respiratory stimulant drug, used in chronic hypoxemic diseases. Almitrine acts in peripheral chemoreceptors and could be a potential treatment for the optimization of chemoreceptors, improving the respiratory control affected by the SARS‐CoV‐2 in patients with COVID-19.

Highlights

Coronavirus disease 2019 (COVID‐19) remains with no specific treatment, despite the efforts of many scientists around the world
To the Editor, Recently, a new pathogenic coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) drives a potential lethal coronavirus disease (COVID‐19), that remains with no treatment, despite the efforts of many scientists around the world
The entrance of Severe Acute Respiratory Syndrome (SARS)-CoV-2 into human host cells is mediated by the angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) receptors, which is expressed in the airway’s epithelium, lung parenchyma, vascular endothelium, renal, intestine, and Central Nervous System (CNS) cells

Summary

Introduction

Coronavirus disease 2019 (COVID‐19) remains with no specific treatment, despite the efforts of many scientists around the world. El virus causa COVID-19 y, a veces, un síndrome respiratorio agudo severo (SARS). Most symptoms in humans are characterized by mild respiratory problems, in older patients there is a greater risk of developing SARS. Patients with COVID-19 develop fever, cough, shortness of breath, and dyspnea, and many might develop pneumonia, respiratory distress, kidney failure, and death[4].

Results

Conclusion